Company profile: Infinant Health
1.1 - Company Overview
Company description
- Provider of infant gut microbiome solutions, offering Evivo Powder, a daily supplement for infants fed any amount of breast milk to establish a protective gut microbiome and support healthy immune function, and B. infantis EVC001, a bacterial strain discovered by Infinant Health and proven pivotal to infant immune health, particularly when combined with breast milk.
Products and services
- B. infantis EVC001: A strain-specific bacterial strain discovered by Infinant Health, pivotal to infant immune health and essential for a healthy microbiome, especially when combined with breast milk
- Evivo Powder: A microbiome-targeted daily powder for infants fed any breast milk that establishes a protective gut microbiome and supports healthy immune function
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Infinant Health
Assembly Bio
HQ: United States
Website
- Description: Provider of oral biologic therapeutics focused on antiviral drug development, including a next-generation capsid assembly modulator for HBV to disrupt replication and prevent new cccDNA, an HBV/HDV pipeline with small molecule inhibitors and interferon-α receptor agonists, and a herpesvirus portfolio targeting high-recurrence genital herpes and transplant-associated herpesviruses, with clinical trials of ABI-H3733 and ABI-4334.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Assembly Bio company profile →
BioCare Copenhagen
HQ: Denmark
Website
- Description: Provider of dietary supplements with microbial components for gastrointestinal problems, infections, and immune enhancement; offers medical nutrition, early life nutrition, pharma solutions, and nutrition improvement. Products include Humiome B2, supporting gut health by delivering a high percentage of vitamin B2 to the colon.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioCare Copenhagen company profile →
4D Pharma
HQ: United Kingdom
Website
- Description: Provider of live biotherapeutics, a novel class of drugs defined by the FDA as biological products containing a live organism, such as bacteria, applicable to the prevention, treatment or cure of disease; developer of MicroRx, a proprietary platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Pharma company profile →
Seres Therapeutics
HQ: United States
Website
- Description: Provider of microbiome therapeutics, including VOWST, an FDA-approved oral microbiota-based therapy to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment; SER-155, an investigational oral microbiome therapeutic aimed at reducing gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients; and a platform to design, test, and manufacture bacterial consortia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seres Therapeutics company profile →
Biocontrol
HQ: United Kingdom
Website
- Description: Provider of a novel system using biological agents to control bacterial infections by Pseudomonas aeruginosa, with proven efficacy and safety even where conventional antibiotics have failed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocontrol company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Infinant Health
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Infinant Health
2.2 - Growth funds investing in similar companies to Infinant Health
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Infinant Health
4.2 - Public trading comparable groups for Infinant Health
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →